Literature DB >> 17127437

Clinical applications of granulocyte-colony stimulating factor.

Lillian Sung1, Yigal Dror.   

Abstract

Granulocyte colony stimulating factor (G-CSF) is a naturally occurring potent neutrophil growth factor. Recombinant human G-CSF has been developed by pharmaceutical companies, and since the late 1980's, multiple clinical trials have explored its efficacy in a variety of medical conditions. These include various inherited and acquired neutropenia, as well as mobilization of hematopoietic stem cells and progenitors for transplantation. Interestingly, in several type of inherited neutropenia where no randomized controlled studies have ever been conducted, its chronic use is considered critical for survival and deemed a standard of care. Unfortunately, it the settings of cancer treatment-related neutropenia and post hematopoietic stem cell transplantation, controversy still prevails whether universal usage of drug is cost effective despite innumerous randomized clinical trials. This review will focus on the clinical applications of G-CSF in the setting of inherited and acquired bone marrow failure, cancer treatment-related neutropenia and hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17127437     DOI: 10.2741/2204

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  The zebrafish granulocyte colony-stimulating factors (Gcsfs): 2 paralogous cytokines and their roles in hematopoietic development and maintenance.

Authors:  David L Stachura; Ondrej Svoboda; Clyde A Campbell; Raquel Espín-Palazón; Ryan P Lau; Leonard I Zon; Petr Bartunek; David Traver
Journal:  Blood       Date:  2013-10-15       Impact factor: 22.113

2.  Modifications in the Kex2 P1' cleavage site in the α-MAT secretion signal lead to higher production of human granulocyte colony-stimulating factor in Pichia pastoris.

Authors:  Sakshi Aggarwal; Saroj Mishra
Journal:  World J Microbiol Biotechnol       Date:  2021-10-16       Impact factor: 3.312

3.  Cytokinetic-driven myeloprotection after cytotoxic chemotherapy: from an old idea to a new clinical approach.

Authors:  Andrea Sbrana; Andrea Antonuzzo; Marco Danova
Journal:  Support Care Cancer       Date:  2022-04-28       Impact factor: 3.359

4.  Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Authors:  Pawel Wiczling; Philip Lowe; Etienne Pigeolet; Frank Lüdicke; Sigrid Balser; Wojciech Krzyzanski
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

Authors:  Athanasia D Panopoulos; Stephanie S Watowich
Journal:  Cytokine       Date:  2008-04-08       Impact factor: 3.861

6.  Optimization of auto-induction medium for G-CSF production by Escherichia coli using artificial neural networks coupled with genetic algorithm.

Authors:  H Tian; C Liu; X D Gao; W B Yao
Journal:  World J Microbiol Biotechnol       Date:  2012-11-07       Impact factor: 3.312

7.  G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.

Authors:  Mark P Rubinstein; Mohamed L Salem; Andrew L Doedens; Caitlin J Moore; Cody Chiuzan; Guillermo L Rivell; David J Cole; Ananda W Goldrath
Journal:  J Hematol Oncol       Date:  2013-10-01       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.